OncoMatch/Clinical Trials/NCT06667687
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
Is NCT06667687 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies ABBV-291 for non-hodgkin's lymphoma.
Treatment: ABBV-291 — Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-291 in adult participants in relapsed or refractory (R/R) NHL, including but not limited to diffuse large b-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL). Adverse events will be assessed. ABBV-291 is an investigational drug being developed for the treatment of NHL. This study will include a dose escalation phase to determine the maximum administered dose (MAD)/Maximum tolerated dose (MTD) of ABBV-291 and a dose expansion/optimization phase to determine the change in disease activity in participants with R/R NHL. Approximately 165 adult participants with multiple NHL subtypes will be enrolled in the study in sites world wide In the dose escalation phase of the study participants will receive escalating Intravenously (IV) infused doses of ABBV-291, until the MAD/MTD is determined. In the dose expansion/optimization phase of the study participants receive IV infused ABBV-291, as part of the approximately 74 month study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, and side effects.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD79B expression (testing required; no eligibility threshold specified)
CD79b expression status will be assessed in all participants
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: therapy known to provide a clinical benefit for their condition
Must be considered relapsed or refractory to, or intolerant of, at least 2 or more prior lines of therapy known to provide a clinical benefit for their condition
Cannot have received: anticancer therapy including chemotherapy, radiotherapy, small molecule, investigational, and biologic agents
Anticancer therapy including chemotherapy, radiotherapy, small molecule, investigational, and biologic agents within 14 days (or at least 5 half-lives, whichever is shorter), prior to the first dose of the study treatment
Cannot have received: CD79b-directed agents (CD79b monoclonal antibody)
CD79b-directed agents (e.g., CD79b monoclonal antibody therapy) within 4 weeks (or at least 5 half-lives, whichever is shorter) prior to the first dose of study treatment
Cannot have received: antibody drug conjugate that consists of a topoisomerase I inhibitor
Prior treatment with an antibody drug conjugate that consists of a topoisomerase I inhibitor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Carolina BioOncology Institute /ID# 265259 · Huntersville, North Carolina
- Willamette Valley Cancer Institute and Research Center /ID# 270945 · Eugene, Oregon
- Texas Oncology - Central/South Texas /ID# 270946 · Austin, Texas
- START Mountain Region /ID# 267592 · West Valley City, Utah
- Virginia Cancer Specialists - Fairfax /ID# 265082 · Fairfax, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify